search

Active clinical trials for "Kidney Neoplasms"

Results 81-90 of 809

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

Renal Cancers

The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.

Active17 enrollment criteria

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell CarcinomaMetastatic Kidney Carcinoma2 more

This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Aldesleukin may stimulate the white blood cells to kill kidney cancer cells. Giving entinostat together with aldesleukin may be a better treatment for metastatic kidney cancer.

Active34 enrollment criteria

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear...

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)8 more

This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.

Active20 enrollment criteria

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Kidney Cancer

The main purpose of this study is to evaluate the effects of the interleukin-2 given in combination with pembrolizumab. Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™. Pembrolizumab is also called Keytruda™, or anti-PD-1 antibody.

Active32 enrollment criteria

Savolitinib vs. Sunitinib in MET-driven PRCC.

CarcinomaCarcinoma7 more

This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.

Active14 enrollment criteria

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced...

Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial Carcinoma22 more

This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues or lymph nodes (locally advanced), or spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab and eribulin mesylate may work better at treating urothelial cancer compared to atezolizumab alone.

Active96 enrollment criteria

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic...

Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial Carcinoma22 more

This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (inoperable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CYT107 is a biological product naturally made by the body that may stimulate the immune system to destroy tumor cells. Giving atezolizumab and CYT107 may work better in treating patients with locally advanced, inoperable, or metastatic urothelial carcinoma compared to atezolizumab alone.

Active75 enrollment criteria

Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney

Renal Cell Carcinoma

This study is evaluating the activity and efficacy of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of kidney cancers.

Active10 enrollment criteria

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)9 more

This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body. Part 1 of this trial will study the safety and the level that adverse effects of the study drug tazemetostat in combination with doxorubicin (current front line treatment) can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug plus doxorubicin versus doxorubicin plus placebo (dummy treatment).

Active58 enrollment criteria

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Kidney Cancer

The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after that. Researchers will also study the safety of these 2-drug sequences.

Active36 enrollment criteria
1...8910...81

Need Help? Contact our team!


We'll reach out to this number within 24 hrs